Medicus Pharma to Detail Oncology Pipeline at Conference
CEO Raza Bokhari will provide updates on three investigational drug candidates in New York and Abu Dhabi this fall.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Do you generally trust the clinical potential of products announced by small biotechnology companies?
Medicus Pharma CEO Raza Bokhari is scheduled to present the company's research pipeline at the BioFuture conference in New York City on October 27, 2026. The presentation will outline ongoing developments for three investigational products, including an antibody-drug conjugate and a microneedle-based therapy for Gorlin syndrome.
Why it matters
As Medicus Pharma transitions its primary R&D focus toward specific oncology indications, its upcoming presentations will clarify the clinical proof-of-concept timelines for its three core investigational assets. The firm is shifting its strategy to prioritize melanoma and skin cancer treatment candidates.
The firm is advancing SkinJect, which uses a dissolvable microneedle patch to deliver the chemotherapy drug doxorubicin directly into basal cell carcinoma lesions. Its other primary asset, CD228V, utilizes a vedotin linker-payload platform, a chemical bridge used to attach cytotoxic drugs to antibodies for targeted cancer cell delivery.
The players
Raza Bokhari
The CEO of Medicus Pharma who oversees the company’s strategic pipeline and research initiatives.
Medicus Pharma
A publicly traded biotechnology firm focused on oncology research and targeted delivery platforms.
The details
SkinJect targets Gorlin syndrome, a genetic condition causing numerous basal cell carcinomas, by injecting medication directly into tumors to minimize systemic toxicity. CD228V is an antibody-drug conjugate (ADC), a class of biotherapeutics designed to bind to specific tumor antigens, while Teverelix functions as a GnRH antagonist, a class of hormones that inhibit the production of sex hormones often used to manage androgen-dependent diseases. These candidates remain in the research-stage, with the FDA having authorized the specific SKNJCT-005 study for the microneedle delivery system.
Timeline
October 27, 2026: Medicus Pharma panel at the BioFuture conference.
October 28, 2026: Conclusion of the BioFuture conference.
November 11, 2026: Commencement of the Global Biotechnology Summit.
November 12, 2026: Keynote address at the Global Biotechnology Summit.
The Tech Race
Medicus Pharma is positioning its pipeline to compete within the crowded field of targeted oncology therapies, particularly in antibody-drug conjugates and localized skin cancer treatments. The firm’s research trajectory depends on successfully moving these assets through clinical validation following the initiation of the SKNJCT-005 study.
Patients with Gorlin syndrome and melanoma will eventually see potential treatment alternatives, but all three core assets remain in the investigational stage without current availability. The upcoming presentations will provide the most significant public update for stakeholders and clinicians interested in the firm's trial roadmap.
The takeaway
Medicus Pharma is focusing its strategy on oncology candidates that leverage distinct delivery platforms. Watch for the clinical data updates presented at the BioFuture conference to determine the firm's progress toward subsequent trial phases.
Further reading
Explore more developments in Biotech to track how emerging platforms and clinical studies are shifting the research landscape.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you generally trust the clinical potential of products announced by small biotechnology companies?
